Literature DB >> 3480871

The value of tumour marker CA 125 in surgical pathology.

I A Koelma1, M Nap, C J Rodenburg, G J Fleuren.   

Abstract

CA 125 is a tumour marker located primarily on non-mucinous epithelial ovarian tumours and which is recognized by the monoclonal antibody OC 125. In this study the value of CA 125 in surgical pathology was assessed. In fresh frozen material, the expression of CA 125 was demonstrated in 82% of 83 epithelial ovarian neoplasms using the indirect immunoperoxidase technique. In addition, all adenocarcinomas of cervix (n = 5) and endometrium (n = 15) tested expressed CA 125, and 25 of 111 (22%) non-gynaecological malignant tumours were positive. The positive cases included 20 breast carcinomas, one carcinoma of the stomach and one of the colon. Using a commercial kit on routinely fixed, paraffin embedded material, CA 125 positivity was demonstrated in 29 of 36 (80%) serous cystadenocarcinomas after pronase pre-treatment of the sections, in contrast to 100% (n = 25) positivity on frozen tissue sections. CA 125 can, therefore, be demonstrated in routinely fixed paraffin embedded material, although the number of positive results is less than in fresh frozen sections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3480871     DOI: 10.1111/j.1365-2559.1987.tb02633.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  8 in total

1.  Immunohistological characterization of a monoclonal antibody (OV632) against epithelial ovarian carcinomas.

Authors:  G J Fleuren; E G Coerkamp; M Nap; L J vd Broek; S O Warnaar
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

2.  Sarcoma-like mural nodules in cystic serous ovarian tumours.

Authors:  T J Clarke
Journal:  J Clin Pathol       Date:  1987-12       Impact factor: 3.411

3.  Immunoreactive determinants of CA 125 in women with endometriosis.

Authors:  O A Mojiminiyi; M E Bramwell; S H Kennedy; B J Shepstone; S M Humm; D H Barlow
Journal:  J Clin Pathol       Date:  1989-12       Impact factor: 3.411

4.  Use of statistical evaluation of antigen profiles in differential diagnosis between colonic and ovarian adenocarcinomas.

Authors:  S C Henzen-Logmans; N W Schipper; L G Poels; K Stolk; P Kenemans; C J Meyer
Journal:  J Clin Pathol       Date:  1988-06       Impact factor: 3.411

5.  CA125 in ovarian tumour tissue at second laparotomy.

Authors:  T S Maughan; R G Fish; M D Shelley; B Jasani; G T Williams; M Adams
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

6.  Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.

Authors:  O Mogensen; B Mogensen; A Jakobsen
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

7.  Asymptomatic primary fallopian tube cancer: an unusual cause of axillary lymphadenopathy.

Authors:  N A Healy; S O Hynes; J Bruzzi; S Curran; M O'Leary; K J Sweeney
Journal:  Case Rep Obstet Gynecol       Date:  2011-12-11

8.  Serum biomarkers for early detection of gynecologic cancers.

Authors:  Yutaka Ueda; Takayuki Enomoto; Toshihiro Kimura; Takashi Miyatake; Kiyoshi Yoshino; Masami Fujita; Tadashi Kimura
Journal:  Cancers (Basel)       Date:  2010-06-14       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.